The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications
By J. Satsangi, M. Silverberg, Severine Vermeire, J. Colombel. Gut, 2006
3,108 citations recorded by the source corpus.
In recent years, investigators have readdressed the complex issues involved in the classification of inflammatory bowel diseases. In 2003, a Working Party of investigators with an interest in the issues involved in disease subclassification was formed with the aim of summarising recent developments in disease classification and establishing an integrated clinical, molecular, and serological classification of inflammatory bowel disease. The results of the Working Party were reported at the 2005 Montreal World Congress of Gastroenterology. Here we highlight the key issues that have emerged from discussions of the Montreal Working Party and the relevance to clinical practice and research activities.
Subfields: Epidemiology, Genetics, Surgery
View Paper: https://www.semanticscholar.org/paper/134f2c6549fab63c9bcc9f9bd9c94b2583d7195f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Genetics
Citations in the corpus
- ACG Clinical Guideline: Ulcerative Colitis in Adults (2019, background): “Extent of the disease should be characterized according to the Montreal classification as proctitis (E1), left-sided colitis (E2), or extensive colitis (E3) (extension proximal to the splenic flexure) (42,43).”
- Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases (2012, neutral): “Infliximab (%) 3 (7) 7 (17) 10 (24) 2 (5) 5 (12) 7 (17) –”
- Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases (2010, background): “The inflammatory bowel diseases (IBD) represent a heterogeneous spectrum of chronic inflammatory disorders of the digestive tract [1, 2].”